2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 335

Interleukin-33 Suppresses Experimental Arthritis through Promoting Foxp3⁺ Regulatory T-Cells and Type-2 Immune Responses in Mice
Abstract Number: 1006

Interleukin-4 As Promising, Anti-Inflammatory Transgene for Gene Therapeutic Application in Joint Diseases
Abstract Number: 2241

Intermittent Analgesic Use and Risk of Pain Exacerbation in Knee Osteoarthritis: A Web Based Case-Crossover Study
Abstract Number: 1999

Internal Medicine Resident Confidence in Rheumatologic and Musculoskeletal Diseases: A Needs Assessment Survey
Abstract Number: 727

International Classification of Functioning, Disability, and Health (ICF) Core Sets for Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) and Idiopathic Pulmonary Fibrosis (IPF) – a Necessary Map to Health Care Provision in the Era of ICD-11
Abstract Number: 2953

International Immunochip Study in the Idiopathic Inflammatory Myopathies Identifies Novel Susceptibility Loci and Confirms HLA As Strongest Genetic Risk Factor
Abstract Number: 2401

Interrupted and Delayed Care in First Nation Patients with Rheumatoid Arthritis: The Best Target for Therapy?
Abstract Number: 2996

Intestinal Pseudo-Obstruction in Patients with Systemic Sclerosis: An Analysis of the Nationwide Inpatient Sample
Abstract Number: 295

Intra-Articular Corticosteroid Injections in Juvenile Idiopathic Arthritis: Results from a UK Prospective Collaborative Study
Abstract Number: 2844

Intracellular Complement C3 Is Exposed on the Cell Surface upon Apoptosis Induction and Participates in the Clearance of Apoptotic Cells By Phagocytes
Abstract Number: 2199

Intravenous Immunoglobulin Therapy for Secondary Hemophagocytic Lymphohistiocytosis : A Retrospective Study of 46 Patients
Abstract Number: 1252

Intravenous Methylprednisolone Pulse Therapy in Severe Inflammatory Eye Disease. a Multicenter Study
Abstract Number: 2191

Intravenous Sodium Thiosulfate for Treatment of Refractory Calcinosis in Rheumatic Disease
Abstract Number: 2181

Investigating Myeloid and Plasmacytoid Dendritic Cell Activation within the Synovium and Peripheral Blood of Rheumatoid Arthritis Patients
Abstract Number: 2182

Investigating the Roles of Factor H-Related Proteins in Systemic Lupus Erythematosus (SLE) and Other Autoimmune Diseases

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].